Chemotherapy News and Research

Latest Chemotherapy News and Research

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

Despite the desperate need for new antibiotics to combat increasingly deadly resistant bacteria, the U.S. Food and Drug Administration (FDA) has approved only one new systemic antibiotic since the Infectious Diseases Society of America (IDSA) launched its 10 x '20 Initiative in 2010 - and that drug was approved two and a half years ago.

22 Apr 2013

New chemical compound offers a promising step for creating potential anti-cancer agents

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.

22 Apr 2013

Study examines link between cognitive complaints and neuropsychological testing abnormalities in breast cancer patients

For many years, breast cancer patients have reported experiencing difficulties with memory, concentration and other cognitive functions following cancer treatment. Whether this mental "fogginess" is psychosomatic or reflects underlying changes in brain function has been a bone of contention among scientists and physicians.

20 Apr 2013

Researchers find new potential target for anti-telomerase cancer therapy

Researchers at UT Southwestern Medical Center have found that alternative splicing - a process that allows a single gene to code for multiple proteins - appears to be a new potential target for anti-telomerase cancer therapy.

20 Apr 2013

Combination therapies may advance treatment for anaplastic thyroid cancer

A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers at Mayo Clinic in Florida.

19 Apr 2013

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the 10th anniversary of his continued cancer-free survival.

19 Apr 2013

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

ADial Pharmaceuticals, LLC, announced today that the U.S. Food and Drug Administration has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder in certain targeted genotypes population only.

19 Apr 2013

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

An Indiana University School of Medicine breast cancer surgeon is pursuing research that will utilize glass, gold, nanotechnology and Greek mythology hoping to vanquish breast cancer that has metastasized to the brain.

19 Apr 2013

Researchers study new ways of taking advantage of caffeine's lethal effects on cancer cells

Researchers from the University of Alberta are abuzz after using fruit flies to find new ways of taking advantage of caffeine's lethal effects on cancer cells-results that could one day be used to advance cancer therapies for people.

19 Apr 2013

Researchers find potential new genetic chemotherapy approach for cancer treatment

Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy.

18 Apr 2013

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

18 Apr 2013

Low bowel cancer survival in the UK likely to be due to differences in staging and treatment

Incomplete diagnostic investigation and failure to get the best treatment are the most likely reasons why survival for bowel cancer patients is lower in the UK than in other comparable countries, according to new research published in the journal Acta Oncologica.

17 Apr 2013

University of Alberta researcher develops polymer platform technology for targeted drug delivery

A University of Alberta researcher is thinking small to find innovative ways to improve the delivery of drugs that can be more easily administered with fewer side-effects.

17 Apr 2013

Survival rate for bowel cancer patients lower in UK, new research finds

17 Apr 2013

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

16 Apr 2013

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Recently, doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment.

16 Apr 2013

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

Australian-based global oncology company, Sirtex Medical Limited (ASX: SRX), has announced the completion of patient recruitment for its global SIRFLOX clinical study which is aimed at expanding the clinical use of its SIR-spheres® microspheres targeted radiation therapy from a last line medical treatment to a standard first-line oncology therapy.

16 Apr 2013

Roundup: Ariz. gov. vetoes bill that would require docs to post prices online, long-term care costs soar in Virginia

Gov. Jan Brewer vetoed legislation Friday that would have required doctors, hospitals and other health care providers to post prices for their most common services, a move the bill's sponsor said was a blow to consumers and driven by industry pressure.

16 Apr 2013

GTx to continue two pivotal Phase III clinical trials of enobosarm

GTx, Inc. today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board, resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

16 Apr 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

New chemical compound offers a promising step for creating potential anti-cancer agents

Study examines link between cognitive complaints and neuropsychological testing abnormalities in breast cancer patients

Researchers find new potential target for anti-telomerase cancer therapy

Combination therapies may advance treatment for anaplastic thyroid cancer

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

Researchers study new ways of taking advantage of caffeine's lethal effects on cancer cells

Researchers find potential new genetic chemotherapy approach for cancer treatment

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Low bowel cancer survival in the UK likely to be due to differences in staging and treatment

University of Alberta researcher develops polymer platform technology for targeted drug delivery

Survival rate for bowel cancer patients lower in UK, new research finds

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Study on targeted liver cancer therapy called SIR-Spheres microspheres completes patient recruitment

Roundup: Ariz. gov. vetoes bill that would require docs to post prices online, long-term care costs soar in Virginia

GTx to continue two pivotal Phase III clinical trials of enobosarm

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in